Genitourinary System Neoplasm

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

A panel of 40 ovarian cancer cell lines with varied mutation profiles was assayed for sensitivity to the cdk4/6 inhibitor palbociclib (PD0332991) via measurement of IC50 values for inhibition of proli… (full text at CIViC)

PMID 21278246 · Konecny et al., 2011 · Open in CIViC

28 renal cell carcinoma cell lines were tested for sensitivity to CDK4/6 inhibitor Palbociclib (PD0332991). 19 were reported sensitive, and 9 resistant. 15 of the 28 cell lines had high levels of Cycl… (full text at CIViC)

PMID 23898052 · Logan et al., 2013 · Open in CIViC

In a retrospective study of 88 ovarian carcinomas, 18 had amplification of CCNE1. Those with amplification had worse overall and disease-free survival.

PMID 20336784 · Nakayama et al., 2010 · Open in CIViC

Small molecule inhibitors PHA-533533 and dinaciclib were used to treat CCNE1 amplified ovarian cancer cell lines. Inhibitors decreased pRb and increased apoptosis.

PMID 24004674 · Etemadmoghadam et al., 2013 · Open in CIViC

Four ovarian cancer cell lines with elevated CCNE1 expression were 40x more sensitive to Cdk2 inhibitor SNS-032 than four cell lines without CCNE1 overexpression. SNS-032 greatly prolonged the surviva… (full text at CIViC)

PMID 26204491 · Yang et al., 2015 · Open in CIViC

The effect of high CCNE1 expression on PD0332991 (palbociclib) sensitivity was observed in cell lines. One PD0332991 sensitive cell line, HEY, was engineered to constitutively express CCNE1 (HEY-CCNE… (full text at CIViC)

PMID 25557169 · Taylor-Harding et al., 2015 · Open in CIViC

High expression of PD-L1 and PD-1 were associated with a favorable prognosis in patients with high grade serous ovarian carcinoma (n = 215 cases).

PMID 26625204 · Darb-Esfahani et al., 2016 · Open in CIViC

Within a multicentre, open-label, phase 3 randomised control trial, investigation of the potential biomarker PD-L1 was found not to potentiate anti-tumor effects in response to atezolizumab in metasta… (full text at CIViC)

PMID 29268948 · Powles et al., 2018 · Open in CIViC

In a clinical study including 59 stage III-IV ovarian cancer patients with peritoneal disseminated tumors, Kaplan-Meier analysis showed a significant association between CD44v6 high expression and wor… (full text at CIViC)

PMID 26250934 · Tjhay et al., 2015 · Open in CIViC

In a clinical trial including 21 patients, CD44v6 expression (prior to and after to NAC) is a predictive factor of response to NAC by multivariate analysis (p = 0.0099 and p = 0.0470). Moreover, CD44v… (full text at CIViC)

PMID 11136572 · Costa et al., 2001 · Open in CIViC

In an in vitro study using docetaxel-resistant PC-3R cells, knockdown with CD44v8-10 siRNAs increased sensitivity to docetaxel (p < 0.05) compared to negative control.

PMID 32642575 · Kato et al., 2020 · Open in CIViC

After second line treatment with cisplatin, 64 patients with positive immunohistochemical staining of CD44v9 show a significant decrease of cancer specific survival rate (p = 0.008). In multivariate a… (full text at CIViC)

PMID 29385995 · Hagiwara et al., 2018 · Open in CIViC

A 62 year old nonsmoker with KRAS and ERBB family wild-type metastatic pulmonary adenocarcinoma was found to have a CD74-NRG1 fusion. The patient achieved a durable response when treated with afatinib… (full text at CIViC)

PMID 28502724 · Gay et al., 2017 · Open in CIViC

A single case of pulmonary mucinous adenocarcinoma in a 62 year old patient was found to have a CD74-NRG1 fusion. Afatinib treatment resulted in symptomatic and radiographic response for 26 weeks, at … (full text at CIViC)

PMID 29169524 · Cheema et al., 2017 · Open in CIViC

In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and redu… (full text at CIViC)

PMID 24240700 · Bajrami et al., 2014 · Open in CIViC

In prostate cancer models, CDK12 loss impaired homologous recombination deficiency and sensitized cells to PARP inhibitors (olaparib, rucaparib, talazoparib, veliparib) in a gene dosage-dependent mann… (full text at CIViC)

PMID 39321214 · Chou et al., 2024 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

In a phase 2 trial, patients with metastatic castration-resistant prostate cancer harboring DNA damage repair (DDR) gene aberrations were treated with olaparib. In gene testing, samples from tumor tis… (full text at CIViC)

Open in CIViC

In retrospective analyses of two large ICI-treated solid tumor cohorts (DFCI n = 789, MSKCC n = 1250), CDKN2A loss-of-function alterations were associated with significantly worse overall survival and… (full text at CIViC)

PMID 34074656 · Adib et al., 2021 · Open in CIViC

Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 lo… (full text at CIViC)

PMID 23898052 · Logan et al., 2013 · Open in CIViC

Preclinical study of CDK4/6 inhibitor PD-0332991 in 28 renal carcinoma cell lines (25 malignant RCC and three non-malignant, transformed cell lines derived from kidney epithelium). Both p15 and p16 lo… (full text at CIViC)

PMID 23898052 · Logan et al., 2013 · Open in CIViC

Expression of c-FLIP (CFLAR) in 50 prostate specimens (assessed by IHC) was increased in castrate-resistant prostate cancer. In-vitro, silencing of CFLAR led to sensitization of two prostate carcinoma… (full text at CIViC)

PMID 22623731 · McCourt et al., 2012 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

Meta-analysis linking CHEK2 1100delC to a higher risk in prostate cancer ((OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00) ).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis linking CHEK2 1100delC to a higher risk of prostate cancer (OR 3.29; 95% confidence interval: 1.85-5.85; P = 0.00).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis of 4 retrospective studies linked CHEK2 I157T to a higher risk of prostate cancer (OR 1.80; 95% confidence interval: 1.51-2.14; P = 0.00).

PMID 26629066 · Wang et al., 2015 · Open in CIViC

Meta-analysis of 2 studies of CHEK2 and prostate cancer showing that the IVS2+1G>A mutation is irrelevant as a predictor of prostate cancer.

PMID 26629066 · Wang et al., 2015 · Open in CIViC

This randomized, open-label, phase 3 trial evaluated the PARP inhibitor olaparib in 387 men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving a n… (full text at CIViC)

PMID 32343890 · de Bono et al., 2020 · Open in CIViC

This phase 3 study evaluated the PARP inhibitor talazoparib in combination with the androgen receptor inhibitor enzalutamide as a first-line treatment in patients with metastatic castration-resistant… (full text at CIViC)

PMID 38049622 · Fizazi et al., 2024 · Open in CIViC

COL1A1::PDGFB fusion is typically found in dermatofibrosarcoma protuberans, but this study revealed it could appear in uterine sarcoma, and the presence of this fusion was suggested as a feature for a… (full text at CIViC)

PMID 30877273 · Croce et al., 2019 · Open in CIViC

Blood mRNA levels of DEFA1, DEFA1B and DEFA3 were associated with response to docetaxel treatment in castration resistant prostate cancer. The discovery cohort consisted of 6 patients, results were va… (full text at CIViC)

PMID 26261420 · Kohli et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were two mutations in D1709E… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1709G.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with one mutation in a Juvenile ovarian granulosa-cell tumor (1/14; 7%). This individual had a somat… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

In this exploratory study of Sertoli-Leydig cell tumors, DICER1 mutations were found in over half of the samples sequenced, but were not found to have any role in tumorigenesis, contrary to what was p… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There were ten mutations in D1709N… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1810H.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%). There was one mutation in D1810N.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103) with high predominance in Sertoli-Lydig cell tumors (26/43; 60%).Two Sertoli-Lydig cell tumors harbo… (full text at CIViC)

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

DICER1 mutations in the RNase IIIb domain were found in 29% of nonepithelial ovarian tumors (n=103). Of the eight mature teratomas that were evaluated, one had a somatic mutation in D1810Y.

PMID 22187960 · Heravi-Moussavi et al., 2012 · Open in CIViC

Sanger sequencing identified DICER1 hotspot mutations in 20 of 32 (63%) ovarian Sertoli–Leydig cell tumors. These mutations were unrelated to tumor differentiation and mostly (16/20, 80%) were E1705K.… (full text at CIViC)

PMID 26428316 · Conlon et al., 2015 · Open in CIViC